Inspire Medical Systems, In a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea (OSA), announced the FDA approval of the Inspire V therapy system  which includes the next generation neurostimulator and the associated Bluetooth patient remote and physician programmer.

Inspire Medical Systems是一家专注于为阻塞性睡眠呼吸暂停（OSA）患者开发和商业化创新微创解决方案的医疗技术公司，该公司宣布FDA批准Inspire V治疗系统，该系统包括下一代神经刺激器和相关的蓝牙患者远程和医生程序员。

The company’s focus remains on operational readiness, which includes product manufacturing and establishing inventory levels to support a full commercial launch in the United States. The company continues to target a soft launch in late 2024 and a full launch in 2025.

该公司的重点仍然是运营准备，其中包括产品制造和建立库存水平，以支持在美国的全面商业推出。该公司的目标是在2024年末实现软发布，并在2025年实现全面发布。